文献速递前列腺癌

双模态前列腺特异性膜抗原靶向探针用于前列腺癌术前正电子发射断层扫描/计算机断层扫描成像与术中荧光成像的首次人体研究

First-in-human Study of a Dual-modality Prostate-specific Membrane Antigen-targeted Probe for Preoperative Positron Emission Tomography/Computed Tomography Imaging and Intraoperative Fluorescence Imaging in Prostate Cancer.
PubMed 文献 · Eur Urol · 2025-04-09

这项首次人体研究评估了双模态PSMA靶向探针68Ga-P3在机器人辅助根治性前列腺切除术中的安全性、最佳剂量和准确性。16例患者接受10、20、40 μg/kg剂量,未发生相关不良事件;2小时肿瘤SUVmax中位数5.3,PET/CT定位灵敏度79.1%、特异度90.4%,术中荧光成像总体NPV 100%、PPV 43.8%、准确率90.9%。40 μg/kg剂量准确率最高为92.3%。

要点

  • 68Ga-P3在10–40 μg/kg剂量下耐受良好,无给药或荧光成像相关不良事件。
  • 68Ga-P3 PET/CT肿瘤定位灵敏度79.1%、特异度90.4%、PPV 81.5%、NPV 89.0%。
  • 术中荧光成像总体NPV 100%、PPV 43.8%、准确率90.9%;40 μg/kg剂量准确率最高92.3%。

核心结论

  • 在PSMA靶向PET成像和荧光引导手术中,68Ga-P3安全可行,为前列腺癌手术管理提供了新工具。

研究设计与样本

  • 首次人体研究,2024年5月至2024年7月共纳入16例患者,每例静脉注射68Ga-P3(10、20、40 μg/kg),放射性活度3.7 MBq/kg。
  • 注射后30、60、120分钟行PET/CT评估生物分布和剂量学;注射后24±6小时行机器人辅助根治性前列腺切除术,使用Firefly荧光成像敏感模式。

主要发现

  • 68Ga-P3耐受良好,无任何与68Ga-P3给药或荧光成像相关的不良事件。
  • 给药后2小时,肿瘤最大标准化摄取值中位数为5.3(4.1-8.1)。
  • 68Ga-P3 PET/CT对肿瘤定位的灵敏度79.1%、特异度90.4%、阳性预测值81.5%、阴性预测值89.0%。
  • 术中荧光成像总体阴性预测值100%、阳性预测值43.8%、准确率90.9%。
  • 全部假阳性部位中88.9%(8/9)被证实为手术切缘邻近的肿瘤;40 μg/kg剂量准确率最高为92.3%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Accurately distinguishing between cancerous and noncancerous tissues during robot-assisted radical prostatectomy (RARP) is a challenge that can increase the risk of residual disease. This study aimed to evaluate the safety, optimal dose and accuracy of a dual-modality prostate-specific membrane antigen (PSMA)-targeted probe (68Ga-P3) for preoperative positron emission tomography (PET)/computed tomography (CT) imaging and intraoperative fluorescence imaging in prostate cancer. METHODS AND SURGICAL PROCEDURE: Each participant received an intravenous chemical dose of 68Ga-P3 (10, 20, and 40 μg/kg), with radioactivity of 3.7 MBq/kg. PET/CT imaging was conducted 30, 60, and 120 min after injection to evaluate its biodistribution and dosimetry. RARP was performed at 24 ± 6 h after injection, in the sensitive mode of Firefly fluorescence imaging. KEY FINDINGS AND LIMITATIONS: Between May 2024 and July 2024, a total of 16 patients were included; 68Ga-P3 was well tolerated without any adverse events related to 68Ga-P3 administration or fluorescence imaging. At 2 h after administration, the median tumor maximum standardized uptake value was 5.3 (4.1-8.1). The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of 68Ga-P3 PET/CT for tumor localization were 79.1%, 90.4%, 81.5%, and 89.0%, respectively. The overall NPV, PPV, and accuracy of intraoperative fluorescence imaging were 100%, 43.8%, and 90.9%, respectively. Of overall false-positive sites, 88.9% (8/9) were confirmed as tumor adjacent to the surgical margin. A dose of 40 μg/kg resulted in the highest accuracy of 92.3%. CONCLUSIONS AND CLINICAL IMPLICATIONS: In PSMA-targeted PET imaging and fluorescence-guided surgery, 68Ga-P3 is safe and feasible for use, offering a novel tool for the surgical management of prostate cancer.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Chen S, Xu H, Chen X, et al. First-in-human Study of a Dual-modality Prostate-specific Membrane Antigen-targeted Probe for Preoperative Positron Emission Tomography/Computed Tomography Imaging and Intraoperative Fluorescence Imaging in Prostate Cancer. Eur Urol. 2025. PMID: 40204598. doi:10.1016/j.eururo.2025.03.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。